Literatur
- 1
Bautmans I, Van Puyvelde K, Mets T.
Sarcopenia and functional decline: pathophysiology, prevention
and therapy.
Acta Clin Belg.
2009;
64
303-316
- 2
Bennani-Baiti N, Davis M P.
Cytokines and
cancer anorexia cachexia syndrome.
Am J Hosp Palliat Care.
2008;
25
407-411
- 3
Delano M J, Moldawer L L.
The origins
of cachexia in acute and chronic inflammatory diseases.
Nutr
Clin Pract.
2006;
21
68-81
- 4
De Vriese C, Delporte C.
Influence of ghrelin
on food intake and energy homeostasis.
Curr Opin Clin
Nutr Metab Care.
2007;
10
615-619
- 5
Eley H L, Russell S T, Tisdale M J.
Role of the dsRNA-dependent protein kinase
(PKR) in the attenuation of protein loss from muscle by insulin
and insulin-like growth factor-1 (IGF-1).
Mol Cell Biochem.
2008;
313
63-69
- 6
Emmelot-Vonk M H, Verhaar H J, Nakhai Pour H R. et al .
Effect of testosterone
supplementation on functional mobility, cognition, and other parameters
in older men: a randomized controlled trial.
JAMA.
2008;
299
39-52
- 7
Evans W J, Morley J E, Argilés J. et al .
Cachexia: a new definition.
Clin Nutr.
2008;
27
793-799
- 8
Fearon K C.
Cancer cachexia: developing multimodal therapy for a multidimensional
problem.
Eur J Cancer.
2008;
44
1124-1132
- 9
Foster A C, Chen C.
Melanocortin-4 receptor
antagonists as potential therapeutics in the treatment of cachexia.
Curr Top Med Chem.
2007;
7
1131-1136
- 10
Fox C B, Treadway A K, Blaszcyk A T, Sleeper R B.
Megestrol
acetate and mirtazapine for the treatment of unplanned weight loss
in the elderly.
Pharmacotherapy.
2009;
29
383-397
- 11
Frost R A, Lang C H.
Protein kinase
B/Akt: a nexus of growth factor and cytokine signaling
in determining muscle mass.
J Appl Physiol.
2007;
103
378-387
- 12
Goldspink G.
Loss of muscle strength during aging studied at the gene level.
Rejuvenation Res.
2007;
10
397-405
- 13
Goodpaster B H, Park S W, Harris T B. et al .
The loss of skeletal muscle strength,
mass, and quality in older adults: the health, aging and body composition
study.
J Gerontol.
2006;
61A
1059-1064
- 14
Hubbard R E, O’Mahony M S, Calver B L, Woodhouse K W.
Nutrition, inflammation, and leptin levels in aging and frailty.
J Am Geriatr Soc.
2008;
56
279-284
- 15 Huber K. Gezielte Ernährungstherapie gegen Tumorkachexie. Onkologie in der Praxis;
2003 Ärztewoche
Wien
- 16
Jackson M J.
Skeletal muscle aging: role of reactive oxygen species.
Crit
Care Med.
2009;
37
S368-371
- 17
Jang Y C, Lustgarten M S, Liu Y. et al .
Increased superoxide in vivo accelerates
age-associated muscle atrophy through mitochondrial dysfunction
and neuromuscular junction degeneration.
FASEB J.
2009; Epub ahead of print;
- 18
Kaminji M M, Inui A.
The role of ghrelin and
ghrelin analogues in wasting disease.
Curr Opin Clin Nutr
Metab Care.
2008;
11
443-451
- 19
Kishioka Y, Thomas M, Wakamatsu J. et al .
Decorin enhances the proliferation and
differentiation of myogenic cells through suppressing myostatin
activity.
J Cell Physiol.
2008;
215
856-867
- 20
Kollias H D, McDermott J C.
Transforming
growth factor-beta and myostatin signaling in skeletal muscle.
J Appl Physiol.
2008;
104
579-587
- 21
Laviano A, Meguid M M, Inui A, Muscaritoli M, Rossi-Fanelli F.
Therapy Insight: cancer anorexia-chachexia-syndrome – when
all you can eat is yourself.
Review Nature Clinical Practice
Oncology.
2005;
2
158-165
- 22
Liu C M, Yang Z, Liu C W. et al .
Effect of RNA oligonucleotide Foxo-1 on muscle
growth in normal and cancer cachexia mice.
Cancer Gene Ther.
2007;
14
945-952
- 23
Lundholm K, Daneryd P, Bosaeus I, Körner U, Lindholm E.
Palliative nutritional intervention in addition to cyclooxygenase
and erythropoietin treatment for patients with malignant disease:
effects on survival, metabolism, and function.
Cancer.
2004;
100
1967-1977
- 24
Lundholm K, Körner U, Gunnebo L. et al .
Insulin treatment in cancer cachexia: effects
on survival, metabolism, and physical functioning.
Clin
Cancer Res.
2007;
13
2699-2706
- 25
Lynch G S, Ryall J G.
Role of beta-adrenoreceptor
signaling in skeletal muscle: implications for muscle wasting and
disease.
Physiol Rev.
2008;
88
729-767
- 26
Lynch G S, Schertzer J D, Ryall J G.
Therapeutic approaches for muscle wasting
disorders.
Pharmacol Ther.
2007;
113
461-487
- 27
Melstrom L G, Melstrom Jr K A, Ding X Z, Adrian T E.
Mechanisms of skeletal muscle degradation and its therapy in
cancer cachexia.
Histol Histopathol.
2007;
22
805-814
- 28
Norman K, Richard C, Lochs H, Pirlich M.
Prognostic impact of disease-related
malnutrition.
Clin Nutr.
2008;
27
5-15
- 29
Ockenga J, Pirlich M, Gastell S, Lochs H.
Tumoranorexie – Tumorkachexie
bei gastrointestinalen Tumoren: Standards und Visionen.
Z
Gastroenterol.
2002;
40
929-936
- 30
Pahor M, Manini T, Cesari M.
Sarcopenia: clinical evaluation, biological markers and other
evaluation tools.
Nutr Health Aging.
2009;
13
724-728
- 31
Pascual Lopez A.
Systematic reviews of megestrol acetate in the treatment of
anorexia-cachexia syndrome.
J Pain Symptom Manage.
2004;
27
360-369
- 32
Pirlich M, Schütz T, Norman K. et al .
The German hospital malnutrition study.
Clin Nutr.
2006;
25
563-572
- 33 Rensing L, Koch M, Rippe B, Rippe V. Mensch im Stress. Psyche,
Körper, Moleküle. Heidelberg: Spektrum
Akademischer Verlag, Elsevier; 2006
- 34
Russell S T, Eley H, Tisdale M J.
Role of reactive oxygen species in protein degradation in murine
myotubes induced by proteolysis-inducing factor and angiotensin
II.
Cell Signal.
2007;
19
1797-1806
- 35
Ryall J G, Schertzer J D, Lynch G S.
Cellular and molecular mechanisms underlying
age-related muscle wasting and weakness.
Biogerontology.
2008;
9
213-228
- 36
Saini A, Faulkner S, Al-Shanti N, Stewart C.
Powerful signal for
weak muscles.
Ageing Res Rev.
2009;
8
251-67
- 37
Sakuma K, Yamaguchi A.
Molecular mechanisms in
aging and current strategies to counteract sarcopenia.
Curr
Aging Sci.
2010;
3
90-101
- 38
Schmitt T L, Martignoni M E, Bachmann I.
Activity of the Akt-dependent anabolic and
catabolic pathways in muscle and liver samples in cancer-related
cachexia.
J Mol Med.
2007;
85
647-654
- 39
Schülke M, Wagner K R, Stolz L E. et al .
Myostatin mutation associated with
gross muscle hypertrophy in a child.
N Engl J Med.
2004;
350
2682-2688
- 40
Sciorati C, Touvier T, Buono R. et al .
Necdin is expressed in cachetic skeletal
muscle to protect fibers from tumor-inducing wasting.
Cell Sci.
2009;
122
1119-1125
- 41
Senf S M, Dodd S L, McClung J M, Judge A R.
Hsp70
overexpression inhibits NF-(kappa)B and Foxo3a transcriptional activities
and prevents skeletal muscle atrophy.
FASEB J.
2008;
22
3836-3845
- 42
Short K R, Vittone J L, Bigelow M L.
Changes in myosin heavy chain mRNA and protein
expression in human skeletal muscle with age and endurance exercise
training.
J Appl Physiol.
2005;
99
95-102
- 43
Strasser F.
Appraisal of current and experimental approaches to the treatment
of cachexia.
Curr Opin Support Palliat Care.
2007;
1
312-316
- 44
Szewczyk N J, Jacobson L A.
Signal-transduction
network and the regulation of muscle protein degradation.
IJBCB.
2005;
37
1997-2011
- 45
Thomas D R.
Loss of skeletal muscle mass in aging: examining the relationship
of starvation, sarcopenia and cachexia.
Clin Nutr.
2007;
26
389-399
- 46
Tisdale M J.
Mechanisms of cancer cachexia.
Physiol Rev.
2009;
89
381-410
- 47
Todorov P T, Wyke S M, Tisdale M J.
Identification and characterization of a
membrane receptor for proteolysis-inducing factor on skeletal muscle.
Cancer Res.
2007;
67
11419-11427
- 48
Tsuchida K.
Targeting myostatin for therapies against muscle-wasting disorders.
Curr Opin Drug Discov Devel.
2008;
11
487-494
- 49
von Haehling S, Lainscak M, Springer J, Anker S D.
Cardiac cachexia:
A systematic overview.
Pharmacol Therapeut.
2009;
121
227-252
- 50
Weyermann P, Dallmann R, Magyar J. et al .
Orally available selective melanocortin-4
receptor antagonists stimulate food intake and reduce cancer-induced
cachexia in mice.
PloS One.
2009;
4
e4774
- 51
Yavuzsen T, Walsh D, Davis M P. et al .
Components of the anorexia-cachexia syndrome:
gastrointestinal symptom correlates of cancer anorexia.
Support
Care Cancer.
2009; Epub ahead of print;
- 52
Zhao J, Brault J J, Schild A. et al .
FOX03 coordinately activates protein degradation
by the autophagic lysosmal and proteasomal pathways in atrophying
muscle cells.
Cell Metab.
2007;
6
472-483
- 53
Zoico E, Roubenoff R.
The role of cytokines
in regulating protein metabolism and muscle function.
Nutr
Rev.
2002;
60
39-51
- 54
Zürcher G.
Medikamentöse Strategien zur Gewichtszunahme bei kachektischen
Patienten.
Aktuelle Ernährungsmedizin.
2004;
27
398-407
Prof. Dr. Ludger Rensing
Institut für Zellbiologie, Biochemie
und Biotechnologie
Universität Bremen, FB 2
NW 2, Leobener Str.
28359 Bremen
Phone: 0421/218-63206
Email: rensing@uni-bremen.de
